Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
2004 1
2005 5
2006 2
2007 1
2008 3
2009 5
2010 1
2013 2
2017 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Results by year
Filters applied: . Clear all
Page 1
A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine.
DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, Koblish M, Lark MW, Violin JD. DeWire SM, et al. Among authors: koblish m. J Pharmacol Exp Ther. 2013 Mar;344(3):708-17. doi: 10.1124/jpet.112.201616. Epub 2013 Jan 8. J Pharmacol Exp Ther. 2013. PMID: 23300227
Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands.
Worm K, Zhou QJ, Saeui CT, Green RC, Cassel JA, Stabley GJ, DeHaven RN, Conway-James N, LaBuda CJ, Koblish M, Little PJ, Dolle RE. Worm K, et al. Among authors: koblish m. Bioorg Med Chem Lett. 2008 May 1;18(9):2830-5. doi: 10.1016/j.bmcl.2008.04.006. Epub 2008 Apr 7. Bioorg Med Chem Lett. 2008. PMID: 18430570
CB2 selective sulfamoyl benzamides: optimization of the amide functionality.
Goodman AJ, Ajello CW, Worm K, Le Bourdonnec B, Savolainen MA, O'Hare H, Cassel JA, Stabley GJ, Dehaven RN, Labuda CJ, Koblish M, Little PJ, Brogdon BL, Smith SA, Dolle RE. Goodman AJ, et al. Among authors: koblish m. Bioorg Med Chem Lett. 2009 Jan 15;19(2):309-13. doi: 10.1016/j.bmcl.2008.11.091. Epub 2008 Nov 27. Bioorg Med Chem Lett. 2009. PMID: 19091565
Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability.
Sellitto I, Le Bourdonnec B, Worm K, Goodman A, Savolainen MA, Chu GH, Ajello CW, Saeui CT, Leister LK, Cassel JA, Dehaven RN, Labuda CJ, Koblish M, Little PJ, Brogdon BL, Smith SA, Dolle RE. Sellitto I, et al. Among authors: koblish m. Bioorg Med Chem Lett. 2010 Jan 1;20(1):387-91. doi: 10.1016/j.bmcl.2009.10.062. Epub 2009 Oct 17. Bioorg Med Chem Lett. 2010. PMID: 19919895
Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
Chu GH, Saeui CT, Worm K, Weaver DG, Goodman AJ, Broadrup RL, Cassel JA, DeHaven RN, LaBuda CJ, Koblish M, Brogdon B, Smith S, Le Bourdonnec B, Dolle RE. Chu GH, et al. Among authors: koblish m. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5931-5. doi: 10.1016/j.bmcl.2009.08.063. Epub 2009 Aug 21. Bioorg Med Chem Lett. 2009. PMID: 19736007
Physical medicine and rehabilitation in acute myocardial infarction.
NEWMAN LB, ANDREWS MF, KOBLISH MO, BAKER LA. NEWMAN LB, et al. Among authors: koblish mo. AMA Arch Intern Med. 1952 Apr;89(4):552-61. doi: 10.1001/archinte.1952.00240040031004. AMA Arch Intern Med. 1952. PMID: 14902164 No abstract available.
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
Le Bourdonnec B, Windh RT, Ajello CW, Leister LK, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, Graczyk TM, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Christ DD, Derelanko MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE. Le Bourdonnec B, et al. Among authors: koblish m. J Med Chem. 2008 Oct 9;51(19):5893-6. doi: 10.1021/jm8008986. Epub 2008 Sep 13. J Med Chem. 2008. PMID: 18788723
18 results